Tau-targeting therapies for Alzheimer disease

EE Congdon, EM Sigurdsson - Nature Reviews Neurology, 2018 - nature.com
Alzheimer disease (AD) is the most common form of dementia. Pathologically, AD is
characterized by amyloid plaques and neurofibrillary tangles in the brain, with associated …

[HTML][HTML] Tau PET imaging in neurodegenerative tauopathies—still a challenge

A Leuzy, K Chiotis, L Lemoine, PG Gillberg… - Molecular …, 2019 - nature.com
The accumulation of pathological misfolded tau is a feature common to a collective of
neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is …

[HTML][HTML] Novel therapeutic approaches for Alzheimer's disease: an updated review

TW Yu, HY Lane, CH Lin - International journal of molecular sciences, 2021 - mdpi.com
Alzheimer's disease (AD) is a progressive neurodegenerative disease and accounts for
most cases of dementia. The prevalence of AD has increased in the current rapidly aging …

[HTML][HTML] Status and challenges of plant-anticancer compounds in cancer treatment

P Garcia-Oliveira, P Otero, AG Pereira, F Chamorro… - Pharmaceuticals, 2021 - mdpi.com
Nowadays, cancer is one of the deadliest diseases in the world, which has been estimated
to cause 9.9 million deaths in 2020. Conventional treatments for cancer commonly involve …

Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity

RD Dorand, J Nthale, JT Myers, DS Barkauskas, S Avril… - Science, 2016 - science.org
Cancers often evade immune surveillance by adopting peripheral tissue–tolerance
mechanisms, such as the expression of programmed cell death ligand 1 (PD-L1), the …

[HTML][HTML] Medical treatment of Cushing's disease: an overview of the current and recent clinical trials

R Pivonello, R Ferrigno, MC De Martino… - Frontiers in …, 2020 - frontiersin.org
Cushing's disease (CD) is a serious endocrine disorder characterized by chronic
hypercortisolism, or Cushing's syndrome (CS), caused by a corticotroph pituitary tumor …

Therapeutic targeting of transcriptional cyclin-dependent kinases

MD Galbraith, H Bender, JM Espinosa - Transcription, 2019 - Taylor & Francis
The fact that many cancer types display transcriptional addiction driven by dysregulation of
oncogenic enhancers and transcription factors has led to increased interest in a group of …

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments

L Xiao, Y Liu, H Chen, L Shen - Cancer Biology & Therapy, 2023 - Taylor & Francis
As a catalytic subunit of the positive transcription elongation factor b (P-TEFb), cyclin-
dependent kinase 9 (CDK9) has been demonstrated to contribute to carcinogenesis. This …

Analyzing the scaffold diversity of cyclin‐dependent kinase inhibitors and revisiting the clinical and preclinical pipeline

D Bhurta, SB Bharate - Medicinal Research Reviews, 2022 - Wiley Online Library
Kinases have gained an important place in the list of vital therapeutic targets because of
their overwhelming clinical success in the last two decades. Among various clinically …

[HTML][HTML] Cheminformatics tools for analyzing and designing optimized small-molecule collections and libraries

N Moret, NA Clark, M Hafner, Y Wang, E Lounkine… - Cell chemical …, 2019 - cell.com
Libraries of well-annotated small molecules have many uses in chemical genetics, drug
discovery, and therapeutic repurposing. Multiple libraries are available, but few data-driven …